Loading…
Quince Therapeutics, Inc. is projected to rise to $27.18 by 2027, a +9% move from its current price of $24.97. QNCX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $23.94 | $24.97 | $26.04 | +0.01% |
| Aug 6 | $23.53 | $24.97 | $26.50 | +0.03% |
| Aug 7 | $23.22 | $24.97 | $26.87 | +0.04% |
| Aug 8 | $22.96 | $24.98 | $27.17 | +0.05% |
| Aug 9 | $22.73 | $24.98 | $27.45 | +0.06% |
| Aug 10 | $22.53 | $24.98 | $27.70 | +0.08% |
| Aug 11 | $22.35 | $24.99 | $27.93 | +0.09% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $22.35 | $24.99 | $27.93 | +0.09% |
| Week 2 | $21.36 | $25.01 | $29.28 | +0.18% |
| Week 3 | $20.64 | $25.03 | $30.36 | +0.26% |
| Week 4 | $20.05 | $25.05 | $31.31 | +0.35% |
| Week 5 | $19.54 | $25.07 | $32.17 | +0.44% |
| Week 6 | $19.10 | $25.10 | $32.98 | +0.53% |
| Week 7 | $18.70 | $25.12 | $33.73 | +0.61% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Quince Therapeutics, Inc. is a biotechnology company focused on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. Its lead asset candidate comprises eDSP, which is in Phase 3, for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.
The AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient\'s own red blood cells, as well as consist of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising kit medical devices, syringe kit, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc.
in August 2022. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Quince Therapeutics, Inc. (QNCX) is a healthcare company trading at $22.00 per share with a market capitalization of $21.52M. It ranks 4847 by market cap.
A major floor 96.5% below — a decisive break under it would weaken the trend.
The nearest floor, 32.9% below — buyers have tended to step in here.
Resistance now sits 6.3% below — it may act as fresh support.
A major ceiling 53.7% above — clearing it would confirm fresh momentum.
Key QNCX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of QNCX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $21.13 | Buy | $21.67 | Buy |
| MA 10 | $19.79 | Buy | $20.28 | Buy |
| MA 20 | $18.87 | Buy | $17.75 | Buy |
| MA 50 | $9.14 | Buy | $12.06 | Buy |
| MA 100 | $5.16 | Buy | $9.67 | Buy |
| MA 200 | $12.79 | Buy | $10.64 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 85.96 | Sell |
| Stoch RSI (14) | 81.75 | Sell |
| CCI (20) | 236.36 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | -0.06 | Sell |
| ROC (12) | 25.89 | Buy |
| Bollinger %B (20,2) | 1.13 | Sell |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 4.93 | Buy |
| Awesome (5,34) | 8.19 | Buy |
| Ultimate (7,14,28) | 86.61 | Sell |
| Momentum (10) | 4.51 | Buy |
| Aroon Osc (25) | 92.00 | Buy |
| Hull MA (9) | 23.30 | Buy |
| ADX (14) | 58.75 | Buy |
| ATR (14) | 0.79 | Info |
The 30-day technical picture is bullish, with RSI14 at 70 and a current price near the $22.00 resistance level. The 50-day simple moving average (SMA50) is $19.43, while the 200-day simple moving average (SMA200) is $218.59. Support is listed at $16.75 and resistance at $22.00. The 30-day range spans from $16.50 to $29.33, and annualized volatility is 80%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $16.00 | $24.97 | $34.85 | 0% | Neutral | |
| $20.62 | $27.18 | $38.46 | +9% | Neutral | |
| $22.75 | $31.42 | $46.92 | +26% | Bullish | |
| $30.51 | $43.80 | $68.18 | +75% | Bullish | |
| $30.89 | $45.91 | $73.96 | +84% | Bullish | |
| $32.53 | $49.93 | $82.85 | +100% | Bullish | |
| $32.63 | $51.62 | $87.95 | +107% | Bullish | |
| $28.41 | $46.24 | $80.67 | +85% | Bullish | |
| $32.67 | $54.68 | $97.47 | +119% | Bullish | |
| $41.99 | $72.17 | $131.26 | +189% | Bullish | |
| $43.34 | $84.42 | $166.74 | +238% | Bullish | |
| $95.60 | $212.44 | $471.81 | +751% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $16.00 | $24.97 | $31.43 | +0.00% |
| September 2026 | $21.94 | $26.35 | $32.81 | +5.53% |
| October 2026 | $20.80 | $25.25 | $31.96 | -4.15% |
| November 2026 | $20.59 | $25.22 | $32.34 | -0.12% |
| December 2026 | $21.75 | $26.86 | $34.85 | +6.50% |
Click any year to see its month-by-month QNCX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect QNCX to range from $16.00 to $34.85 through 2026. The $24.97 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The QNCX price prediction for 2027 points to an average of $27.18 (low $20.62, high $38.46) — a potential gain of +9% on today's $24.97. Price action looks broadly range-bound.
In 2028, QNCX is projected to trade between $22.75 and $46.92, averaging $31.42 — a potential gain of +26% from today's $24.97. That is up +16% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Quince Therapeutics, Inc.'s 2029 outlook centres on $43.80, within a $30.51 to $68.18 range. That is up +39% on the projected 2028 average. That marks a +75% change versus current levels. Momentum favours further upside here.
By 2030, QNCX could reach as high as $73.96, with a base case around $45.91 and support toward $30.89 — roughly +84% from $24.97. Buyers look set to stay in control over this stretch.
Expect QNCX to range from $32.53 to $82.85 through 2031. The $49.93 average target implies a +100% move from current prices. That is up +9% on the projected 2030 average. Momentum favours further upside here.
The QNCX price prediction for 2032 points to an average of $51.62 (low $32.63, high $87.95) — a potential gain of +107% on today's $24.97. Buyers look set to stay in control over this stretch.
In 2033, QNCX is projected to trade between $28.41 and $80.67, averaging $46.24 — a potential gain of +85% from today's $24.97. That is -10% versus the projected 2032 average. Momentum favours further upside here.
Quince Therapeutics, Inc.'s 2034 outlook centres on $54.68, within a $32.67 to $97.47 range. That is up +18% on the projected 2033 average. That marks a +119% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, QNCX could reach as high as $131.26, with a base case around $72.17 and support toward $41.99 — roughly +189% from $24.97. Momentum favours further upside here.
Expect QNCX to range from $43.34 to $166.74 through 2040. The $84.42 average target implies a +238% move from current prices. That is up +17% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The QNCX price prediction for 2050 points to an average of $212.44 (low $95.60, high $471.81) — a potential gain of +751% on today's $24.97. Momentum favours further upside here.
Investing $1,000 in QNCX today (≈ 40.056079 QNCX) could be worth
$8,509.67
+$7,509.67 (+751%) by 2050 · US Dollar
Based on the average projected QNCX price of $212.44 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in QNCXwould be worth at today's price.
$1,000 invested in QNCX on Jul 31, 2025 (≈ 59.171599 QNCX) would be worth
$1,477.22
+$477.22 (+47.7%) today · 1.48× · US Dollar
Based on a QNCX entry price of $16.9 vs. today's $24.97.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $17.85 | $1,398.21 | +39.8% |
| 1 month ago | $16.75 | $1,490.45 | +49.0% |
| 3 months ago | $1.33 | $18,770.68 | +1777.1% |
| 6 months ago | $1.8 | $13,869.44 | +1286.9% |
| 1 year ago | $16.9 | $1,477.22 | +47.7% |
| All time (5.0y) ago | $691.6 | $36.1 | -96.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our QNCX forecast.
Our base-case forecast reaches $50.00 around 2032.
Implied market cap at $50.00: $48.9M
The multi-year forecast shows a bullish trajectory, with 2026 expected to average $22.00 and a max of $31.28 (min $16.00). By 2027 the average is $24.13 and max $34.39 (min $18.19), and by 2028 the average rises to $28.62 with a max of $43.11 (min $20.56). By 2029 the average is $40.50 and the max $63.64 (min $27.94), and by 2030 the average reaches $41.97 with a max $68.31 (min $27.92), with an estimated ROI of 90.8 and a bullish sentiment.
In 2031 the average is $46.15 (max $77.44, min $29.70) with ROI 109.8, and 2032 shows average $47.84 (max $82.47, min $29.83) with ROI 117.5. The 2033 forecast is $42.07 (max $74.29, min $25.45) with ROI 91.2, and 2034 is $51.67 (max $93.29, min $30.36) with ROI 134.9. By 2035 the average is $69.03 (max $127.19, min $39.44) with ROI 213.8, followed by 2040 at $80.55 (max $161.47, min $40.32) with ROI 266.1.
The long-run view for 2050 shows an average of $205.68 (max $464.63, min $92.56) and an ROI of 834.9, continuing a bullish momentum while noting these are estimates rather than guarantees and subject to risks.
Tap a question to reveal the answer.
In 2030, the forecast shows min $27.92, avg $41.97, max $68.31, with an ROI of 90.8 and a bullish sentiment.
Forecasts show a bullish sentiment across multiple years, with the average price rising from $22.00 in 2026 to $205.68 in 2050 and an ROI reaching 834.9 by 2050. These are estimates and carry risk; they are not guarantees.
Yes—the forecast max for 2035 is $127.19 and for 2040 is $161.47, indicating potential to surpass $100 in later years within the forecast window.
Current price is $22.00 and market capitalization is $21.52M.
The 30-day range is $16.50 to $29.33, RSI14 is 70, SMA50 is $19.43, SMA200 is $218.59, with support at $16.75 and resistance at $22.00; sentiment is BULLISH and annualized volatility is 80%.
Quince Therapeutics, Inc. Community Discussion
0Share your Quince Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.